BRIEF published on 04/15/2025 at 10:05, 1 year ago IOmx Therapeutics Gains Approval for IOMX-0675 Clinical Trials Immune Response IOmx Therapeutics IOMX-0675 Clinical Trial Approval Solid Tumor Therapy
BRIEF published on 04/15/2025 at 10:05, 1 year ago IOmx Therapeutics obtient l'approbation pour les essais cliniques sur IOMX-0675 Réponse Immunitaire IOmx Therapeutics IOMX-0675 Approbation Des Essais Cliniques Thérapie Des Tumeurs Solides
PRESS RELEASE published on 04/15/2025 at 10:00, 1 year ago iOmx Therapeutics Receives Regulatory Approval of Clinical Trial Application for IOMX-0675 iOmx Therapeutics receives regulatory approval for clinical trial application of IOMX-0675, a LILRB1/LILRB2 dual-targeting antibody, to reverse immune suppression in solid tumors Regulatory Approval Clinical Trial Application IOmx Therapeutics IOMX-0675 Solid Tumor
BRIEF published on 12/19/2024 at 14:05, 1 year 3 months ago IOmx Therapeutics Advances IOMX-0675 with Clinical Trial Application Cancer Treatment Clinical Trial Application IOmx Therapeutics IOMX-0675 Immunosuppressive Receptors
BRIEF published on 12/19/2024 at 14:05, 1 year 3 months ago IOmx Therapeutics fait progresser IOMX-0675 avec une application d'essai clinique Traitement Du Cancer Thérapeutique IOmx IOMX-0675 Demande D'essai Clinique Récepteurs Immunosuppresseurs
PRESS RELEASE published on 12/19/2024 at 14:00, 1 year 3 months ago iOmx Therapeutics submits Clinical Trial Application for IOMX-0675 iOmx Therapeutics submits Clinical Trial Application for IOMX-0675, a dual-targeting antibody demonstrating strong anti-tumor potential by reprogramming myeloid cells and restoring cytotoxic T cell function Clinical Trial Application IOmx Therapeutics IOMX-0675 Immunosuppressive Receptors Anti-tumor Potential
BRIEF published on 08/22/2024 at 10:05, 1 year 7 months ago IOmx Therapeutics Initiates Phase Ib with OMX-0407 Cancer Therapy Clinical Trial IOmx Therapeutics OMX-0407 Phase Ib
BRIEF published on 08/22/2024 at 10:05, 1 year 7 months ago IOmx Therapeutics lance la phase Ib avec OMX-0407 Essai Clinique Thérapie Contre Le Cancer OMX-0407 Phase Ib Thérapeutique IOmx
PRESS RELEASE published on 08/22/2024 at 10:00, 1 year 7 months ago iOmx Therapeutics Initiates Phase Ib with OMX-0407 iOmx Therapeutics initiates Phase Ib clinical trial with OMX-0407, showing favorable safety profile and anti-tumor activity in solid tumors. Expansion phase opens in kidney cancer and angiosarcoma Solid Tumors Clinical Trial IOmx Therapeutics OMX-0407 Phase Ib
BRIEF published on 06/27/2024 at 10:05, 1 year 9 months ago IOmx Therapeutics Appoints Florian Schmid as New Chief Financial Officer Chief Financial Officer Biopharmaceutical Leadership IOmx Therapeutics Florian Schmid
Published on 04/18/2026 at 04:00, 1 day 6 hours ago Formation Metals Responds to OTC Markets Request on Recent Promotional Activity
Published on 04/18/2026 at 02:00, 1 day 8 hours ago AI/ML Innovations Announces Completion of Share Issuance
Published on 04/18/2026 at 01:35, 1 day 9 hours ago Medicure Announces Resignation of President and Chief Operating Officer
Published on 04/18/2026 at 01:00, 1 day 9 hours ago Onco-Innovations Strengthens Executive Leadership with Appointment of Dr. Islam Mohamed as Chief Medical Officer and Stephen M. Novak as Chief of Research and Development
Published on 04/18/2026 at 00:00, 1 day 10 hours ago Redwood AI Announces Collaboration with Aidos Innovations, Aimed at Enhancing Public Safety Collaboration with B.C. Government, Canadian Federal and Local Law Enforcement Agencies to Tackle the Fentanyl Crisis in British Columbia
Published on 04/18/2026 at 00:05, 1 day 10 hours ago ESCMID Global: Maternal RSV vaccination cuts infant hospitalisation risk by over 80%, major UKHSA study finds
Published on 04/17/2026 at 21:39, 1 day 13 hours ago Linedata Services: Mise à disposition du Document d’Enregistrement Universel 2025 incluant le Rapport Financier Annuel 2025
Published on 04/17/2026 at 20:33, 1 day 14 hours ago LLB General Meeting 2026 – Shareholders approve all proposals of the Board of Directors
Published on 04/17/2026 at 19:30, 1 day 15 hours ago KAP AG: REFINANCING CONCEPT AGREED; NEW SYNDICATED LOAN SECURES FLEXIBILITY FOR THE ONGOING TRANSFORMATION PROCESS
Published on 04/17/2026 at 20:30, 1 day 14 hours ago ALTAREA - Déclaration d’opérations sur actions propres
Published on 04/17/2026 at 19:00, 1 day 15 hours ago Cegedim : Publication du Document d’Enregistrement Universel 2025
Published on 04/17/2026 at 19:00, 1 day 15 hours ago Cegedim: Release of its 2025 Universal Registration Document
Published on 04/17/2026 at 17:45, 1 day 17 hours ago Carrefour announces the sale of its minority stake in CarrefourSA in Turkey to Aydın
Published on 04/17/2026 at 17:45, 1 day 17 hours ago Carrefour annonce la cession de sa participation minoritaire dans CarrefourSA en Turquie à Aydın
